Literature DB >> 17685959

Is laparoscopic colectomy for cancer cost-effective relative to open colectomy?

Julian L Hayes1, P Hansen.   

Abstract

BACKGROUND: Laparoscopic-assisted colectomy (LAC) for cancer has been shown to be safe, with equivalent long-term survival rates to conventional open colectomy (OC) and better short-term patient outcomes. However, LAC tends to require more operating theatre time and disposable equipment. This study investigated, in the context of the New Zealand public hospital system, the extent to which LAC for cancer is cost-effective relative to OC.
METHODS: Estimates of the hospital resources used and patient recovery times for LAC and OC for colorectal cancer were obtained from a meta-analysis of published international randomized controlled trials. Using prices from a representative New Zealand public hospital, the additional resources for LAC (relative to OC) were summed to obtain an estimate of LAC's total incremental (additional) cost. The recovery time savings from LAC were also represented in quality-adjusted life years (QALY), enabling a cost-utility analysis of LAC, which was subjected to a one-way sensitivity analysis.
RESULTS: On average, a LAC costs New Zealand public hospitals $1267 (range: $259-$3808; all dollars referred to are New Zealand dollars) more than an OC. Average recovery time savings of 12 and 33 days (from two randomized controlled trials) translate into QALY gains of 0.018 and 0.049. Thus, relative to an OC, an LAC costs $38 and $106 per recovery day saved, or $70 389 and $25 857 (combined range: $14 389-$211 556) per QALY gained.
CONCLUSION: LAC for cancer appears to be cost-effective relative to OC (per recovery day saved and QALY gained, respectively) for the lower of the average cost estimates and is probably not cost-effective for the higher estimate. Expected future reductions in operating times, conversion rates and postoperative stays will further improve cost-effectiveness.

Entities:  

Mesh:

Year:  2007        PMID: 17685959     DOI: 10.1111/j.1445-2197.2007.04226.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  13 in total

1.  MIS in the management of colon and rectal cancer: consensus meeting of the Colorectal Cancer Association of Canada.

Authors:  Christopher M Schlachta; Shady Ashamalla; Andy Smith
Journal:  Surg Endosc       Date:  2013-08-31       Impact factor: 4.584

Review 2.  Appraising the quality of care in surgery.

Authors:  Erik K Mayer; Andre Chow; Justin A Vale; Thanos Athanasiou
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

3.  Learning laparoscopic colectomy during colorectal residency: what does it take and how are we doing?

Authors:  Sharon Stein; Jonah Stulberg; Bradley Champagne
Journal:  Surg Endosc       Date:  2011-09-22       Impact factor: 4.584

Review 4.  Laparoscopic surgery for benign and malign diseases of the digestive system: indications, limitations, and evidence.

Authors:  Markus Alexander Küper; Friederike Eisner; Alfred Königsrainer; Jörg Glatzle
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

5.  A cost comparison of laparoscopic and open colon surgery in a publicly funded academic institution.

Authors:  Krista M Hardy; Josephine Kwong; Kristen B Pitzul; Ashley S Vergis; Timothy D Jackson; David R Urbach; Allan Okrainec
Journal:  Surg Endosc       Date:  2013-11-21       Impact factor: 4.584

6.  The potential economic value of screening hospital admissions for Clostridium difficile.

Authors:  S M Bartsch; S R Curry; L H Harrison; B Y Lee
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-30       Impact factor: 3.267

7.  Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota.

Authors:  Stefan D Holubar; Kirsten Hall Long; Edward V Loftus; Bruce G Wolff; John H Pemberton; Robert R Cima
Journal:  Dis Colon Rectum       Date:  2009-11       Impact factor: 4.585

8.  Cost-effective laparoscopic cholecystectomy.

Authors:  M Slater; M I Booth; T C B Dehn
Journal:  Ann R Coll Surg Engl       Date:  2009-09-25       Impact factor: 1.891

9.  Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.

Authors:  Jiahe Chen; Cynthia L Gong; Matthew M Hitchcock; Marisa Holubar; Stanley Deresinski; Joel W Hay
Journal:  Clin Microbiol Infect       Date:  2021-04-17       Impact factor: 13.310

10.  A comparison of injured patient and general population valuations of EQ-5D health states for New Zealand.

Authors:  Ross Wilson; Paul Hansen; John Langley; Sarah Derrett
Journal:  Health Qual Life Outcomes       Date:  2014-02-18       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.